SKYRIZI’s Approval For Ulcerative Colitis Treatment Expands AbbVie’s Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight
AbbVie’s rapidly expanding Humira successor, SKYRIZI, is already achieving impressive sales growth. This IL-23 inhibitor is set to capture an…
